Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer

The Journal of Urology
David R LiArnold I Chin

Abstract

Cisplatin based chemotherapy regimens form the basis of systemic bladder cancer treatment, although they show limited response rates and efficacy. Recent molecular analysis of bladder cancer revealed a high incidence of mutations in chromatin regulatory genes, suggesting a therapeutic avenue for histone deacetylase inhibitors. We investigated the ability of the novel histone deacetylase inhibitor AR-42 to synergize with cisplatin in preclinical models of bladder cancer. We assessed the ability of the pan-histone deacetylase inhibitor AR-42 with and without cisplatin to destroy bladder cancer cells by survival and apoptosis assays in vitro, and by growth and differentiation in an in vivo xenograft model. We also assessed the response to the bladder cancer stem cell population by examining the effect of AR-42 on the CD44(+)CD49f(+) population with and without cisplatin. Synergy was calculated using combination indexes. The AR-42 and cisplatin combination synergistically destroyed bladder cancer cells via apoptosis and it influenced tumor growth and differentiation in vivo. When tested in the CD44(+)CD49f(+) bladder cancer stem cell population, AR-42 showed greater efficacy with and without cisplatin. AR-42 may be an attractive no...Continue Reading

References

Sep 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Samuel K KulpChing-Shih Chen
Oct 16, 2007·Journal of Translational Medicine·Michael T BuckleyIman Osman
Apr 29, 2008·Advances in Experimental Medicine and Biology·Sharmila Shankar, Rakesh K Srivastava
Oct 1, 2008·Cancer Letters·Olaf WittIna Oehme
Jul 29, 2009·Journal of Hematology & Oncology·David SiegelSyed Rizvi
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Keith Syson ChanIrving L Weissman
Aug 18, 2009·BJU International·Akira OzawaMasayoshi Yokoyama
Aug 9, 2011·Anti-cancer Drugs·Stefan ValloRoman A Blaheta
Feb 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Jens-Peter VolkmerKeith S Chan
Feb 10, 2012·Expert Review of Anticancer Therapy·Ross M Drayton, James W F Catto
Apr 27, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·H Miles Prince, Michael Dickinson
Jun 8, 2012·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Shih-Han HungHow Tseng
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Mar 15, 2014·BMC Clinical Pathology·Cédric PoyetGlen Kristiansen
Jun 25, 2014·Proceedings of the National Academy of Sciences of the United States of America·Shereen JamaladdinShaun M Cowley

❮ Previous
Next ❯

Citations

Jun 1, 2015·Biochemical and Biophysical Research Communications·Weihong XuJie Shen
Aug 26, 2015·Drug Development Research·Saira R AliMichael Z Michael
Oct 6, 2018·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Wei-Chou LinKuo-How Huang
Nov 12, 2020·Aging·Xinmiao YanZhiwei Cao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis